Dr. Reddy's Laboratories ... (RDY)
NYSE: RDY
· Real-Time Price · USD
13.77
-0.15 (-1.08%)
At close: May 01, 2025, 12:25 PM
-1.08% (1D)
| Bid | 13.75 |
| Market Cap | 11.47B |
| Revenue (ttm) | 311.31B |
| Net Income (ttm) | 53.68B |
| EPS (ttm) | 0.76 |
| PE Ratio (ttm) | 18.11 |
| Forward PE | 0.2 |
| Analyst | Buy |
| Ask | 13.78 |
| Volume | 429,511 |
| Avg. Volume (20D) | 2,167,736 |
| Open | 13.85 |
| Previous Close | 13.92 |
| Day's Range | 13.75 - 13.87 |
| 52-Week Range | 12.26 - 16.89 |
| Beta | 0.48 |
About RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finish...
Sector Healthcare
IPO Date Apr 11, 2001
Employees 27,048
Stock Exchange NYSE
Ticker Symbol RDY
Website https://www.drreddys.com
Analyst Forecast
According to 1 analyst ratings, the average rating for RDY stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 23.50% from the latest price.
Stock ForecastsNext Earnings Release
Dr. Reddy's Laboratories Limited is scheduled to release its earnings on May 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-6.23%
Dr. Reddy's Laboratories shares are trading lower....
Unlock content with
Pro Subscription
10 months ago
+4.65%
Dr. Reddy's Laboratories shares are trading higher. The company on Wednesday announced it signed a definitive agreement with Haleon for purchase of shares of Northstar Switzerland SARL to acquire its global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy category outside of the United States.
